...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants
【24h】

Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants

机译：Palivizumab Praphylaxis对早产儿随后复发性喘息的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND OBJECTIVES: Palivizumab effectively prevents severe respiratory syncytial virus (RSV) disease in preterm infants. Our objective was to test whether palivizumab prophylaxis given to preterm infants during the first RSV season reduces the incidence of subsequent recurrent wheezing up to 3 years of life. METHODS: We conducted an observational prospective multicenter (52 registered hospitals in Japan) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed for 3 years. During the 2007-2008 RSV season, the decision to administer palivizumab was made based on standard medical practice. In April 2008, 52 hospitals were recruited. Study participants were prospectively followed to the age of 3 years. Parents of study subjects reported the infants' physician's assessment of recurrent wheezing, used a report card and a novel mobile phone-based reporting system by using the Internet. The primary end point was the incidence of physician-diagnosed recurrent wheezing. RESULTS: Of 444 preterm infants enrolled, 349 received palivizumab during the first 6 months of life and 95 infants did not. Physiciandiagnosed recurrent wheezing was observed in 6.4% and 18.9% of infants in the treated and untreated groups, respectively (P , .001). This difference remained significant after adjustment for known risk factors of recurrent wheezing (P , .001). CONCLUSIONS: Palivizumab prophylaxis administered to preterm infants 33 to 35 weeks' gestational age is associated with a significantly lower incidence of recurrent wheezing during the first 3 years of life. Pediatrics 2013;132:811-818.
机译：背景和目标：Palivizumab有效地防止了早产儿的严重呼吸道同性恋病毒（RSV）疾病。我们的目的是测试第一次RSV季节前对早产儿给出现的帕尔昔单抗预防是否会降低随后的经常性喘息的发病率长达3年的生命。方法：我们在早产儿患者中进行了一个观察前瞻性多中心（日本的52名注册医院）病例对照研究，早产儿33至35周，持续3年。在2007 - 2008年RSV季节期间，根据标准医疗实践制定了管理巴利人民的决定。 2008年4月，招募了52家医院。学习参与者被前瞻性遵循3岁。学习主题的父母报告了婴儿的医生对经常性喘息的评估，通过使用互联网使用报告卡和基于新的移动电话的报告系统。主要终点是医生诊断的复发性喘息的发生率。结果：444名早产儿报名，在前6个月内接受了Palivizumab，95个婴儿没有。在治疗和未经处理的基团中的6.4％和18.9％的婴儿中观察到物理师Diagnosed复发性喘息（p，.001）。在调整复发性喘息的危险因素（P，0.001）的危险因素调整后，这种差异仍然显着。结论：对早产儿33至35周的妊娠期妊娠期妊娠期妊娠期妊娠期妊娠期妊娠期的预防性与生命的前3年中的复发性喘息的发病率显着降低。 2013年儿科; 132：811-818。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号